CamPaix Medical Secures Tens of Millions of RMB in Series A Funding to Advance Innovative Breast Cancer Prevention and Treatment Solutions

VCBeat has learned at the earliest opportunity,Kangpai Medical Technology (Suzhou) Co., Ltd.(hereinafter referred to as“Kangpai Medical”) recently announced the completion of a joint investment by Qianhang Capital and Boyong InvestmentRMB tens of millions in Series A financingFinancing. The proceeds from this round of financing will be used to accelerate the company's existing breast cancer-related products inCommercial Implementation in China and Abroad, while driving the company toComprehensive Portfolio of Advanced Breast Cancer Prevention and Treatment Products.

Kangpai Medical, established in 2019, is dedicated to deepening its expertise in the specialized field of breast health, developing internationally competitive equipment for breast cancer screening, diagnosis, and treatment, serving the global market, and filling domestic gaps. Its core team comprises renowned overseas-returning scholars and experts, senior technical specialists from internationally prominent medical device manufacturers, and seasoned industry professionals, supported by a network of top-tier clinical expert advisors both in China and abroad.

Konpai Medical launched its first product in 2020—Intraoperative Specimen Imaging System for Breast Cancer, primarily used for minimally invasive breast biopsy, surgery, and pathological sampling. During breast biopsy, it confirms the acquisition of the target lesion to avoid omission; during breast surgery, it assesses surgical margins to reduce the likelihood of reoperation; and it assists the pathology department in accurately sampling submitted specimens, thereby ensuring accurate pathological results.

Kangpai Medical Intraoperative Specimen Imaging System for Breast Cancer

This product can also be used as a scientific research instrument forSmall Animal Imaging, Seed Screening, Jewelry and Cultural Relic Identificationand other fields, with extensive applications and a wide range of use cases.

Breast cancer is the most common malignant tumor worldwide. According to data from the International Agency for Research on Cancer (IARC) of the World Health Organization, there were 19.29 million new cancer cases globally in 2020, with breast cancer accounting for 2.26 million new cases, ranking first among all cancers.

In China, breast cancer is also the most common malignant tumor among women, with approximately 416,000 new cases in 2020, accounting for 18.4% of global cases. The average age at diagnosis for breast cancer in China is 48.65 years, nearly 13 years earlier than the average diagnostic age of 61 years in the United States. Breast cancer in China is characterized by low rates of early diagnosis, low breast-conserving surgery rates, low survival rates in advanced stages, and a rapidly increasing incidence rate, making it the “number one killer” of women’s health.

With socioeconomic development and changes in lifestyle, various breast diseases have shown a continuous upward trend in recent years, with a noticeable shift toward younger age groups, driven by environmental and lifestyle factors such as childlessness, delayed childbearing, anxiety, obesity, and increased exposure to exogenous estrogens (found in certain medications, health supplements, and cosmetics). Consequently, the diagnosis and treatment of breast cancer have become increasingly urgent.

Preoperative breast biopsy specimen photography systems and intraoperative specimen imaging systems available on the market are monopolized by foreign giants, resulting in prohibitively high equipment prices that hinder widespread adoption.

Kangpai Medical’s Intraoperative Specimen Imaging System is the first of its kind in China, filling a domestic gap. The product features precision, efficiency, and intelligence. Its self-developed image optimization algorithm, combined with repeatedly optimized, high-performance key components, ensures that image quality fully reaches the advanced international standard for similar products. With an image resolution of up to 10 lp/mm, it outperforms international competitors. The optimized workflow and contact-free operation throughout the process significantly improve surgeons’ efficiency. Rich graphical tools and automatic outlining of suspected calcifications help physicians rapidly identify calcifications and surgical margins during tense operations, enabling precise decision-making, enhancing surgical quality, and reducing the likelihood of reoperation.

Kangpai Medical’s breast specimen imaging system has applied for or obtained nearly 50 intellectual property rights and secured all necessary regulatory approvals in major global markets. The product is widely sold in the United States, Western Europe, the United Kingdom, and China, receiving extensive positive feedback from users.

Regarding this round of financing, Peng Sheng, founder of Kangpai MedicalHe stated, “In today’s world, competition among major powers is primarily a contest in science and technology. As an entrepreneur who has returned from overseas, I remain true to my original aspiration. It is truly inspiring to have the opportunity to leverage my overseas education and years of accumulated experience, in collaboration with capital partners, to develop world-class products in China that can compete directly with leading global manufacturers in European and American markets. Meanwhile, seizing the historical opportunity of domestic substitution, Kangpai is also engaging in deep collaboration with domestic clinical experts to serve clinical practice and drive continuous improvement, thereby contributing to the care of breast cancer patients in China while delivering returns to investors.”

Qiu Wei, Partner at Qianhang Capitalstated: “Breast cancer is a key area of focus and support for the Chinese government, as it significantly impacts people’s health, well-being, and quality of life. We are highly optimistic about this sector. Over the past three years since its establishment, despite the challenges posed by the pandemic, Kangpai Medical has maintained rapid growth under the leadership of Mr. Peng. The company has swiftly launched its products, secured market access, established a global sales network, and successfully entered European and American markets. We are confident in Kangpai’s future development.”

Chen Cheng, head of Boyong Investment, stated: “The founders and team of Kangpai Medical possess profound technical expertise and extensive industry resources. The executive partner of Boyong Investment is Boji Venture Capital, in which Boji Medicine, an A-share listed company, holds a stake. We are highly optimistic about the future development of Kangpai Medical and will actively collaborate with the company to facilitate its rapid growth.”

Qianxing Capital is a professional equity investment firm headquartered in Guangzhou. Its core team is characterized by a rational and pragmatic approach to investment management, strong networking resources, and keen market insight. The firm focuses on investing in early-stage technology enterprises with long-term growth potential, aiming to be a companion to future industry leaders. To date, several of its portfolio companies have successfully listed on the STAR Market, the Shanghai Main Board, and the Shenzhen ChiNext.